New Frontiers in the Treatment and Prevention of Migraines: A Closer Look at the Role of Emerging CGRP Targeted Therapies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 12, 2018 to July 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Amgen, Lilly USA LLC, and Teva Pharmaceuticals

Migraine is a major neurological disease that affects more than 36 million men, women and children in the United States. Migraine headache is the most common type of headache presented by patients that seek medical treatment, and the World Health Organization (WHO) has ranked migraine in the top fifteen most disabling medical conditions. In many patients with migraine headache, their pain is unrelieved, and recurrence of migraine is a common reason for patient dissatisfaction with treatment. The diagnosis of a migraine is based on signs and symptoms and neuroimaging tests are not necessary to diagnose migraine but may be used to find other causes of headaches in those whose examination and history do not confirm a migraine diagnosis. Patients with frequent migraines and/or who experience functional disability need preventative migraine treatment however currently available migraine therapy is often inadequate. Fortunately for patients who suffer from migraine headaches, a new class of therapy is emerging that has shown to offer vastly improved efficacy and safety over traditional treatment regimens. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are under clinical investigation and look to offer healthcare professionals a new and improved armamentarium in the treatment and prevention of migraines. CGRP monoclonal antibodies are specifically designed to bind to and inhibit the activity of CGRP that may prevent or significantly reduce the frequency of monthly migraine headache days in patients with episodic and chronic migraine and cluster headache. The role of CGRP in migraine has been verified by basic research and several therapies are currently undergoing late stage clinical trials.

Upon Completion of this activity, participants will be able to:

  • Examine key clinical trial information, including safety and efficacy data, on emerging CGRP monoclonal antibodies in the treatment and prevention of migraines

  • Compare and contrast different CGRP agents in development for the treatment of migraines

  • Describe the diagnostic approach to migraines, including differential diagnosis from other conditions causing headaches

  • Integrate strategies to improve patient communication/counseling about migraine triggers and treatment to optimize outcomes

  • Discuss the prevalence, pathophysiology, epidemiology, and burden of illness associated with migraine headaches, with an emphasis on managed care implications

Faculty: Deborah I. Friedman, MD, MPH, FAHS
Departments of Neurology, Neurotherapeutics, and Ophthalmology
University of Texas Southwestern Medical Center


Dr. Friedman serves on an advisory board for Alder BioPharmaceuticals, Amgen, Avanir, Biohaven Pharmaceuticals, Supernus, Teva and Zosano. She serves as a consultant for Avanir, electroCore, Eli Lilly and Promius. She has received grant/research support from Autonomic Technologies, Axon Optics, Eli Lilly, Merck, Teva and Zosano. She serves on the speaker's bureau for Allergan, Amgen, Avanir and Supernus. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Amgen, Lilly USA LLC, and Teva Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue